voriconazole
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Prophylaxis Of Invasive Fungal Infections
Conditions
Prophylaxis Of Invasive Fungal Infections
Trial Timeline
Feb 1, 2005 → Apr 1, 2008
NCT ID
NCT00143312About voriconazole
voriconazole is a approved stage product being developed by Pfizer for Prophylaxis Of Invasive Fungal Infections. The current trial status is completed. This product is registered under clinical trial identifier NCT00143312. Target conditions include Prophylaxis Of Invasive Fungal Infections.
What happened to similar drugs?
1 of 12 similar drugs in Prophylaxis Of Invasive Fungal Infections were approved
Approved (1) Terminated (2) Active (10)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (15)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01092832 | Phase 3 | Terminated |
| NCT00836875 | Phase 3 | Terminated |
| NCT00855101 | Phase 1 | Completed |
| NCT00721578 | Pre-clinical | Completed |
| NCT00556998 | Phase 2 | Completed |
| NCT00455364 | Approved | Terminated |
| NCT00300677 | Approved | Completed |
| NCT01660334 | Pre-clinical | Completed |
| NCT01151085 | Pre-clinical | Completed |
| NCT00288197 | Approved | Completed |
| NCT00159822 | Phase 2/3 | Completed |
| NCT00136968 | Phase 1 | Completed |
| NCT00143312 | Approved | Completed |
| NCT00174473 | Phase 1/2 | Completed |
| NCT00647907 | Approved | Completed |
Competing Products
20 competing products in Prophylaxis Of Invasive Fungal Infections